Human papillomavirus vaccination: Where to now?

Sexually Transmitted Infections

Volumn 87, Issue SUPPL. 2, 2011, Pages

  Garland, Suzanne M ^a,b,c  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; CONDYLOMA ACUMINATUM; CYTOLOGY; GENITAL TRACT CANCER; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MALE HOMOSEXUAL; OROPHARYNX CANCER; PAPANICOLAOU TEST; PENIS CANCER; PRIORITY JOURNAL; SEXUAL HEALTH; SHORT SURVEY; UTERINE CERVIX CANCER; VAGINA CANCER; VIRUS LIKE AGENT; VIRUS TRANSMISSION; VULVA CANCER;

ADOLESCENT; CANCER VACCINES; DEVELOPING COUNTRIES; DRUG COSTS; FEMALE; HUMANS; MALE; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 82555193765     PISSN: 13684973     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/sextrans-2011-050182     Document Type: Short Survey

References (11)

1. Zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 1977;78:1-30.
2. Wallboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19. (Pubitemid 29406813)
3. Garland SM, Steben M, Sings H, et al. Natural history of genital warts: Analysis of the placebo arm of two randomized phase iii trials of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. J Infect Dis 2009;199:805-14.
4. Kjær SK, Tran TN, Sparen P, et al. The Burden of Genital Warts: A Study of nearly 70,000 women from the general female population in the 4 nordic countries. J Infect Dis 2007;196:1447-54. (Pubitemid 351411979)
5. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
6. Garland SM, Hernandez AM, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43. (Pubitemid 46740303)
7. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
8. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2010;11:39-44.
9. Brotherton JML, Fridman M, May CL, et al. Early eff ect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085-92.
10. Heffernan ME, Garland SM, Kane MA. Global reduction of cervical cancer with human papillomavirus vaccines: insights from the hepatitis B virus vaccine experience. Sex health 2010;7:383-90.
11. Garland SM. Prevention strategies against human papillomavirus in males. Gynecol Oncol 2010;117:S20-5.